Eren, Orhan OnderArtac, MehmetBoruban, Melih CemYavas, OzlemArslan, UgurBasaranoglu, Metin2020-03-262020-03-2620091357-05601559-131Xhttps://dx.doi.org/10.1007/s12032-008-9133-4https://hdl.handle.net/20.500.12395/23349Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.en10.1007/s12032-008-9133-4info:eu-repo/semantics/closedAccessHepatitis BCytotoxic chemotherapyReactivationCancerLamivudineArticle26438639219021003Q2WOS:000272045400002Q4